AWR vs CTRI

AWR exhibits stable financial health with a Piotroski F-Score of 6/9, indicating moderate strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock appears fairly valued with a current price of $73.16 near the analyst target of $81.00 and intrinsic value estimate of $81.76, despite trading above the conservative Graham Number of $44.06. Solid profitability metrics—such as a 33.96% operating margin and 13.78% ROE—contrast with a bearish technical trend and weak insider sentiment. Revenue and earnings growth remain positive year-over-year, but recent quarterly volatility and limited analyst coverage warrant caution.

CTRI exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9, indicating robust operational improvements. However, this fundamental health is completely decoupled from its market valuation, with the current price of $34.74 trading at a massive premium to both the Graham Number ($6.98) and Intrinsic Value ($7.38). Despite explosive YoY earnings growth, the company has missed analyst estimates in four consecutive quarters, and the current P/E of 138.96 is unsustainable. The stock is currently trading at its 52-week high while analyst target prices ($31.34) have already fallen below the current market price.